Arcutis Biotherapeutics (ARQT) Debt to Equity (2021 - 2025)
Arcutis Biotherapeutics (ARQT) has 5 years of Debt to Equity data on record, last reported at $0.58 in Q4 2025.
- For Q4 2025, Debt to Equity fell 15.49% year-over-year to $0.58; the TTM value through Dec 2025 reached $0.58, down 15.49%, while the annual FY2025 figure was $0.58, 15.49% down from the prior year.
- Debt to Equity reached $0.58 in Q4 2025 per ARQT's latest filing, down from $0.69 in the prior quarter.
- Across five years, Debt to Equity topped out at $4.3 in Q3 2023 and bottomed at $0.24 in Q4 2021.
- Average Debt to Equity over 5 years is $1.17, with a median of $0.78 recorded in 2025.
- Peak YoY movement for Debt to Equity: skyrocketed 562.87% in 2023, then plummeted 70.1% in 2024.
- A 5-year view of Debt to Equity shows it stood at $0.24 in 2021, then skyrocketed by 288.25% to $0.94 in 2022, then surged by 141.19% to $2.28 in 2023, then tumbled by 70.1% to $0.68 in 2024, then dropped by 15.49% to $0.58 in 2025.
- Per Business Quant database, its latest 3 readings for Debt to Equity were $0.58 in Q4 2025, $0.69 in Q3 2025, and $0.78 in Q2 2025.